Seminars in Oncology
Volume 35, Issue 3 , Pages 251-261 , June 2008

Concurrent Chemotherapy and Re-irradiation for Locoregionally Recurrent Head and Neck Cancer

  • Joseph K. Salama

      Affiliations

    • Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL.
    • Cancer Research Center, University of Chicago, Chicago, IL.
    • Corresponding Author InformationAddress correspondence to Joseph K. Salama, MD, Department of Radiation and Cellular Oncology, 5758 S Maryland Ave, MC 9006, Chicago, IL 60637.
    • ,
  • Everett E. Vokes

      Affiliations

    • Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL.
    • Cancer Research Center, University of Chicago, Chicago, IL.
    • Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL.

References 

  1. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–1952
  2. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–1944
  3. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–2098
  4. Brockstein B, Haraf DJ, Rademaker AW, Kies MS, Stenson KM, Rosen F, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol. 2004;15:1179–1186
  5. Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, et al. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006;98:441–450
  6. Lin K, Patel SG, Chu PY, Matsuo JM, Singh B, Wong RJ, et al. Second primary malignancy of the aerodigestive tract in patients treated for cancer of the oral cavity and larynx. Head Neck. 2005;27:1042–1048
  7. Schwartz LH, Ozsahin M, Zhang GN, Touboul E, De Vataire F, Andolenko P, et al. Synchronous and metachronous head and neck carcinomas. Cancer. 1994;74:1933–1938
  8. Spector JG, Sessions DG, Haughey BH, Chao KS, Simpson J, El Mofty S, et al. Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx. Laryngoscope. 2001;111:1079–1087
  9. Vikram B, Strong EW, Shah JP, Spiro R. Second malignant neoplasms in patients successfully treated with multimodality treatment for advanced head and neck cancer. Head Neck Surg. 1984;6:734–737
  10. Cooper JS, Pajak TF, Rubin P, Tupchong L, Brady LW, Leibel SA, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys. 1989;17:449–456
  11. Bairati I, Meyer F, Gelinas M, Fortin A, Nabid A, Brochet F, et al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst. 2005;97:481–488
  12. Ganly I, Patel SG, Matsuo J, Singh B, Kraus DH, Boyle JO, et al. Results of surgical salvage after failure of definitive radiation therapy for early-stage squamous cell carcinoma of the glottic larynx. Arch Otolaryngol Head Neck Surg. 2006;132:59–66
  13. McLaughlin MP, Parsons JT, Fein DA, Stringer SP, Cassisi NJ, Mendenhall WM, et al. Salvage surgery after radiotherapy failure in T1-T2 squamous cell carcinoma of the glottic larynx. Head Neck. 1996;18:229–235
  14. Wong LY, Wei WI, Lam LK, Yuen AP. Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck. 2003;25:953–959
  15. Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ, Million RR. Salvage surgery following radiation failure in squamous cell carcinoma of the supraglottic larynx. Int J Radiat Oncol Biol Phys. 1995;32:605–609
  16. Marcial VA, Hanley JA, Ydrach A, Vallecillo LA. Tolerance of surgery after radical radiotherapy of carcinoma of the oropharynx. Cancer. 1980;46:1910–1912
  17. Temam S, Pape E, Janot F, Wibault P, Julieron M, Lusinchi A, et al. Salvage surgery after failure of very accelerated radiotherapy in advanced head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2005;62:1078–1083
  18. Mabanta SR, Mendenhall WM, Stringer SP, Cassisi NJ. Salvage treatment for neck recurrence after irradiation alone for head and neck squamous cell carcinoma with clinically positive neck nodes. Head Neck. 1999;21:591–594
  19. Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck (A phase III study of the EORTC Head and Neck Cancer Cooperative Group). Ann Oncol. 1994;5:521–526
  20. Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer. 2004;101:2222–2229
  21. Hitt R, Irigoyen A, Nuñez J, Grau J, Garcia Saenz J, Pastor M, et al. Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC). [abstract] J Clin Oncol. 2007;25(Suppl 18):6012
  22. Kim ES, Kies MS, Glisson BS, Tsao A, Ginsberg LE, Holsinger FC, et al. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. [abstact] J Clin Oncol. 2007;25(Suppl 18):6013
  23. Emami B, Bignardi M, Spector GJ, Devineni VR, Hederman MA. Reirradiation of recurrent head and neck cancers. Laryngoscope. 1987;97:85–88
  24. Stevens KR, Britsch A, Moss WT. High-dose reirradiation of head and neck cancer with curative intent. Int J Radiat Oncol Biol Phys. 1994;29:687–698
  25. Peiffert D, Pernot M, Malissard L, Aletti P, Hoffstetter S, Kozminski P, et al. Salvage irradiation by brachytherapy of velotonsillar squamous cell carcinoma in a previously irradiated field: results in 73 cases. Int J Radiat Oncol Biol Phys. 1994;29:681–686
  26. Weichselbaum RR, Beckett MA, Schwartz JL, Dritschilo A. Radioresistant tumor cells are present in head and neck carcinomas that recur after radiotherapy. Int J Radiat Oncol Biol Phys. 1988;15:575–579
  27. Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm—general principles. Nat Clin Pract Oncol. 2007;4:86–100
  28. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27:131–146
  29. Schmidt-Ullrich RK, Contessa JN, Dent P, Mikkelsen RB, Valerie K, Reardon DB, et al. Molecular mechanisms of radiation-induced accelerated repopulation. Radiat Oncol Investig. 1999;7:321–330
  30. Uchida D, Kawamata H, Omotehara F, Nakashiro K, Kimura-Yanagawa T, Hino S, et al. Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int J Cancer. 2001;93:489–496
  31. Khodarev NN, Beckett M, Labay E, Darga T, Roizman B, Weichselbaum RR. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci U S A. 2004;101:1714–1719
  32. Dey S, Spring PM, Arnold S, Valentino J, Chendil D, Regine WF, et al. Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. Clin Cancer Res. 2003;9:1557–1565
  33. Connell PP, Jayathilaka K, Haraf DJ, Weichselbaum RR, Vokes EE, Lingen MW. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol. 2006;28:1113–1119
  34. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature. 1998;394:287–291
  35. DeLaney TF, Afridi N, Taghian AG, Sanders DA, Fuleihan NS, Faller DV, et al. 13-Cis-retinoic acid with alpha-2a-interferon enhances radiation cytotoxicity in head and neck squamous cell carcinoma in vitro. Cancer Res. 1996;56:2277–2280
  36. Vokes EE, Beckett M, Karrison T, Weichselbaum RR. The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines. Oncology. 1992;49:454–460
  37. Hong WK, Bromer R. Chemotherapy in head and neck cancer. N Engl J Med. 1983;308:75–79
  38. Spencer SA, Harris J, Wheeler RH, Machtay M, Schultz C, Spanos W, et al. RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys. 2001;51:1299–1304
  39. De Crevoisier R, Bourhis J, Domenge C, Wibault P, Koscielny S, Lusinchi A, et al. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol. 1998;16:3556–3562
  40. Haraf DJ, Weichselbaum RR, Vokes EE. Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Ann Oncol. 1996;7:913–918
  41. Salama JK, Vokes EE, Chmura SJ, Milano MT, Kao J, Stenson KM, et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2006;64:382–391
  42. Milano MT, Vokes EE, Salama JK, Stenson KM, Kao J, Witt ME, et al. Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys. 2005;61:1096–1106
  43. Chmura SJ, Vokes EE, Garofalo M, Stenson K, Witt M, Weichselbaum RR, et al. Long-term outcome of re-irradiation with concomitant chemotherapy for locally recurrent squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2003;57(Suppl):S409–S410
  44. Brockstein B, Haraf DJ, Stenson K, Fasanmade A, Stupp R, Glisson B, et al. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol. 1998;16:735–744
  45. Kramer NM, Horwitz EM, Cheng J, Ridge JA, Feigenberg SJ, Cohen RB, et al. Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies. Head Neck. 2005;27:406–414
  46. Langer CJ, Duffy K, Horwitz EM, Litwin S, Rosvold E, Schol J, et al. Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naive locally advanced upper aerodigestive malignancy. Cancer Invest. 2006;24:164–173
  47. Horwitz EM, Harris J, Langer CJ, Nicolaou N, Kies M, Curran W, et al. Concurrent split course hyperfractionated radiotherapy (Hfx RT), cisplatin (DDP) and paclitaxel (P) in patients with recurrent, previously irradiated squamous cell carcinoma of the head and neck (SCCHN): update of RTOG 9911. [abstract] J Clin Oncol. 2005;23(Suppl 16):5577
  48. Janot F, de Raucourt D, Castaing M, Bardet E, Dolivet G. Re-irradiation combined with chemotherapy after salvage surgery in head and neck carcinoma: a randomized trial from the GETTEC and GORTEC groups. [abstract] J Clin Oncol. 2006;24(Suppl 18):5508
  49. Spencer S, Wheeler R, Peters G, Meredith R, Beenken S, Nabel L, et al. Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer. Head Neck. 2003;25:118–122
  50. Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081–2086
  51. Spencer SHJ, Wheeler R, Mactay M, Schultz C, Spanos W, Rotman M, et al. Late effects of RTOG-9610: re-irradiation and chemotherapy in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys. 2003;57:S307
  52. Machtay M, Rosenthal DI, Chalian AA, Lustig R, Hershock D, Miller L, et al. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;59:72–77
  53. Ang KK, Jiang GL, Feng Y, Stephens LC, Tucker SL, Price RE. Extent and kinetics of recovery of occult spinal cord injury. Int J Radiat Oncol Biol Phys. 2001;50:1013–1020
  54. De Crevoisier R, Domenge C, Wibault P, Koscielny S, Lusinchi A, Janot F, et al. Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. Cancer. 2001;91:2071–2076
  55. Kasperts N, Slotman BJ, Leemans CR, de Bree R, Doornaert P, Langendijk JA. Results of postoperative reirradiation for recurrent or second primary head and neck carcinoma. Cancer. 2006;106:1536–1547
  56. Upile T, Triaridis S, Kirkland P, Archer D, Searle A, Irving C, et al. The management of carotid artery rupture. Eur Arch Otorhinolaryngol. 2005;262:555–560
  57. Skelly CL, Gallagher K, Fairman RM, Carpenter JP, Velazquez OC, Parmer SS, et al. Risk factors for restenosis after carotid artery angioplasty and stenting. J Vasc Surg. 2006;44:1010–1015
  58. Haddad R, Tishler R, Wirth L, Norris CM, Goguen L, Sullivan C, et al. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2006;132:678–681
  59. Urba S, Wolf G, Eisbruch A, Worden F, Lee J, Bradford C, et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol. 2006;24:593–598
  60. Cohen EE, Rosine D, Haraf DJ, Loh E, Shen L, Lusinchi A, et al. Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;67:678–684
  61. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol. 2006;24:2098–2104
  62. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999;59:3374–3378
  63. Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res. 2003;9:1957–1971
  64. Seiwert TY, Haraf DJ, Cohen EE, Stenson K, Mauer AM, Dekker A, et al. A phase I study of bevacizumab (B) with fluorouracil (F) and hydroxyurea (H) with concomitant radiotherapy (X) (B-FHX) for poor prognosis head and neck cancer (HNC). [abstract] J Clin Oncol. 2006;24(Suppl 18):5530
  65. Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, Hanna NN, et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med. 1995;1:786–791
  66. Mundt AJ, Vijayakumar S, Nemunaitis J, Sandler A, Schwartz H, Hanna N, et al. A phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res. 2004;10:5747–5753
  67. Sulman EP, Schwartz DL, Morrison WH, Rosenthal DI, Chao KS, Ahamada A, et al. IMRT re-irradiation for locoregionally recurrent or in-field second primary head and neck cancer. Int J Radiat Oncol Biol Phys. 2006;66:S412–S413
  68. Jereczek-Fossa BA, Krengli M, Orecchia R. Particle beam radiotherapy for head and neck tumors: radiobiological basis and clinical experience. Head Neck. 2006;28:750–760
  69. Luu QT, Loredo LN, Archambeau JO, Yonemoto LT, Slater JM, Slater JD. Fractionated proton radiation treatment for pediatric craniopharyngioma: preliminary report. Cancer J. 2006;12:155–159
  70. Wilson VC, McDonough J, Tochner Z. Proton beam irradiation in pediatric oncology: an overview. J Pediatr Hematol Oncol. 2005;27(8):444–448
  71. Dendale R, Lumbroso-Le Rouic L, Noel G, Feuvret L, Levy C, Delacroix S, et al. Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO). others Int J Radiat Oncol Biol Phys. 2006;65(3):780–787
  72. Fuss M, Loredo LN, Blacharski PA, Grove RI, Slater JD. Proton radiation therapy for medium and large choroidal melanoma: preservation of the eye and its functionality. Int J Radiat Oncol Biol Phys. 2001;49(4):1053–1059
  73. Gragoudas ES, Lane AM, Munzenrider J, Egan KM, Li W. Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. Trans Am Ophthalmol Soc. 2002;100:43–48discussion 48-9
  74. Hara I, Murakami M, Kagawa K, Sugimura K, Kamidono S, Hishikawa Y, et al. Experience with conformal proton therapy for early prostate cancer. Am J Clin Oncol. 2004;27(4):323–327
  75. Trabulsi EJ, Valicenti RK. Dose escalation with proton-beam boost for low-risk prostate cancer. Nat Clin Pract Urol. 2006;3(5):256–257
  76. Van Waes C, Chang AA, Lebowitz PF, Druzgal CH, Chen Z, Elsayed YA, et al. Inhibition of nuclear factor kappaB and target genes during combined therapy with proteosome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2005;63:1400–1412

PII: S0093-7754(08)00073-0

doi: 10.1053/j.seminoncol.2008.03.010

Seminars in Oncology
Volume 35, Issue 3 , Pages 251-261 , June 2008

Article Tools